Changes in Executive Management at Sosei

22-Jan-2018 - Sosei Group Corporation announced that Dr. Fiona Marshall has resigned from her position as Executive Vice President and Chief Scientific Officer of Sosei to assume a senior role outside the Company. Dr. Marshall will leave Sosei at the end of February 2018. “As a co-founder of Heptares, I am ...

Sosei - GBP 35 Million for an Equity Stake and Acquisition Option Agreement in MiNA Therapeutics

Potential acquisition tied to clinical milestones of lead candidate

03-May-2017 - Sosei Group Corporation and MiNA Therapeutics Limited announced that the companies have entered into a definitive agreement under which Sosei will make an investment in and acquire an exclusive option to potentially acquire MiNA Therapeutics, a private UK biopharmaceutical company and pioneer in ...

Sosei appoints Andrew Oakley as CFO

20-Jan-2017 - Sosei Group Corporation announces the appointment of Andrew Oakley as Chief Financial Officer (CFO) effective from February 1 2017. Mr Oakley will be based in Sosei’s Tokyo offices. Mr Oakley will succeed Mr Hidetoshi Torami who has resigned from Sosei for personal reasons. Mr Oakley, a Chartered ...

Sosei Acquires Heptares Therapeutics for up to USD 400 million

Combination Creates a Leading Global Biopharmaceutical Company with a Major Drug Discovery and Development Hub in the UK

24-Feb-2015 - Sosei Group Corporation announces that it has acquired Heptares Therapeutics Limited. Sosei has acquired 100% of Heptares’ share capital for USD 180 million in cash consideration and up to USD 220 million contingent upon the successful progression of the company’s pipeline and platform. The Group ...

Sosei Assigns AD 923 Assets to Pharmasol

09-Oct-2009 - Sosei Group Corporation announced that Sosei R&D Ltd., its wholly owned UK subsidiary, has entered into an agreement to assign its rights to the assets of AD 923, an optimised, sublingual formulation of the opioid analgesic fentanyl for the treatment of cancer breakthrough pain, as well as to ...

Sosei Announces Update on Phase I Trials for SD118

28-Nov-2007 - Sosei Group Corporation announced an update on the status of its collaborative project SD118, which is under development for the treatment of neuropathic pain. SD118 has commenced a multiple dose ascending Phase I study and the initial single ascending dose Phase I study to explore higher doses ...

Sosei and Vectura Announce Start of Phase II Clinical Study with NVA237 in the USA

08-Aug-2007 - Sosei Group Corporation and Vectura Group plc announced the commencement of a Phase II clinical study in the USA, by Novartis, with NVA237, a once daily long acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). This follows the publication on the ...

Sosei announces progression of SD118 for the treatment of neuropathic pain towards Phase 1 studies

26-Feb-2007 - Sosei Group Corporation announced that its collaborative project SD118, which is under development for the treatment of neuropathic pain, has successfully completed regulatory pre-clinical studies and will now be progressed into Phase 1 clinical trials. SD118 is being jointly developed with ...

Sosei Announces Agreement With Mundipharma For Ad 923

27-Jun-2006 - Sosei Co. Ltd announced that it has entered into an agreement with Mundipharma International Corporation Limited for the development and commercialisation of AD 923, Sosei's novel sublingual fentanyl spray for cancer breakthrough pain, in Europe and other international markets, excluding North ...

Arakis completes Phase I trials of AD 337 in fibromyalgia syndrome

02-Nov-2005 - Sosei Co. Ltd announced that its wholly-owned subsidiary Arakis Ltd, has successfully completed Phase I single and multidose studies of AD 337, a novel enantiomer of an approved centrally acting non-opioid analgesic, which is under investigation for the treatment of fibromyalgia syndrome. AD 337 ...